Mercy Health Saint Mary's

Summary

Mercy Health Saint Mary's is a medical facility located in Grand Rapids, Michigan. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Ovarian Cancer and other specialties. Mercy Health Saint Mary's is involved with conducting 306 clinical trials across 458 conditions. There are 3 research doctors associated with this hospital, such as Kathleen J. Yost, Muhammad Farooq, and Jason Bennett.

Top PIs

Clinical Trials running at Mercy Health Saint Mary's

Lung Cancer

Breast Cancer

Breast cancer

Cancer

Pancreatic Cancer

Non-Small Cell Lung Cancer

Ovarian Cancer

Melanoma

Cutaneous Melanoma

Colorectal Cancer

Thoracotomy vs Thoracoscopy

for Metastatic Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.

Recruiting

2 awards

Phase 3

7 criteria

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.

Recruiting

2 awards

Phase 3